Eltrombopag ITP denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for eltrombopag itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues a Not-FDA-Approved Denial for Eltrombopag in ITP

This denial category — "not FDA approved" — almost always reflects a coding mismatch, a claim submitted for a population subgroup the plan's system does not automatically recognize as within the FDA label, or an administrative error in how the prior-authorization request was documented. Eltrombopag (Promacta) carries FDA approval for chronic ITP in adults and in eligible pediatric patients as described in the full prescribing label. When a claim is filed for a patient whose age, ITP subtype, or clinical context does not match the plan's pre-coded approval pathways, the system may generate this denial even though the use is on-label.

## Why This Denial Is Appealable

Because this denial rests on a factual premise — that the drug lacks FDA approval for the use — it is directly rebutted by the FDA-approved label. No clinical debate is required; this is a documentation appeal. Under ACA §2719, non-grandfathered plans must allow internal appeal and independent external review. Under ERISA §503, employer-plan participants have the right to a full-and-fair review with a written explanation. You generally have 180 days from the denial date to file an internal appeal, and approximately 4 months after a final internal denial to request external review. Expedited review is available when clinical urgency is present.

## Concrete Appeal Steps

1. Attach the FDA-approved prescribing label: Download the current label from the FDA's Drugs@FDA database. Highlight the section confirming the indication for ITP and any age-specific approvals relevant to your patient. 2. Verify the procedure and diagnosis codes: Confirm with the prescribing pharmacy and billing provider that the submitted diagnosis code accurately reflects chronic ITP (not a related but distinct condition) and that the drug code matches the approved product. 3. Submit an internal appeal with the label and a cover letter citing the specific FDA indication. 4. Request external review if the internal appeal is upheld — an independent reviewer is required to recognize FDA approval as controlling.

## Documentation to Gather

• FDA label: the current full prescribing information confirming the ITP indication, pulled directly from Drugs@FDA.
• Diagnosis documentation: hematology records confirming the patient has chronic ITP, matching the approved indication.
• Prescriber attestation: a letter from the treating physician stating that the prescription is for the FDA-approved indication of chronic ITP and is not an off-label use.
• Claim coding review: a written confirmation from the pharmacy or billing provider that procedure, diagnosis, and drug codes were submitted correctly.

## Criteria-Mapping Structure

For a not-FDA-approved denial, the rebuttal is straightforward:

| Denial Premise | Rebuttal Evidence | |---|---| | Drug is not FDA approved for this use | FDA prescribing label — ITP indication section (attached) | | Patient population not covered by approval | Label age/indication language matching patient's diagnosis and demographics | | Claim coding does not match approved indication | Corrected claim with accurate ICD-10 and drug code, if applicable |

Always download the most current version of the FDA-approved prescribing information for eltrombopag (Promacta) from Drugs@FDA before submitting, as label language can change with supplemental approvals. Cross-reference the UHC not-FDA-approved policy to ensure your rebuttal matches each criterion the plan applied.